Fatty Liver Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We used real-time polymerase chain reaction (RT-PCR) analysis to evaluate the hepatic and intestinal expression level of all genes studied (TLR2, TLR4, TLR9, LXRα, SREBP1C, ACC1, FAS, PPARα, CPT1α, CROT, SREBP2, ABCA1, ABCG1 and FXR in the liver; TLR2, TLR4, TLR5, TLR9, GLP-1R, DPP-4, FXR and PPARɣ in the jejunum) in 82 women with MO with normal liver histology (NL, n = 29), SS (n = 32), and NASH (n = 21).
|
31388096 |
2020 |
Fatty Liver Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
As FXR partly regulates PPARα, we compared resolution of NASH and changes in hepatic PPARα and FXR gene expression following Diet and RYGB.
|
30206765 |
2019 |
Fatty Liver Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In vivo studies showed that MP treatment activated PPARα expression, that in turns, promoted β-oxidation protein and gene expressions, suppressed TNFα, MCP1, TGFβ1 and Colla1 protein and gene expression levels, contributing to the prevention of NASH.
|
30579258 |
2019 |
Fatty Liver Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The absence of an approved therapeutic agent for NASH is the reason for investigating saroglitazar (SAR) which showed promising effects as a dual PPAR-α/γ agonist in recent studies on NASH.
|
30737662 |
2019 |
Fatty Liver Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, these findings provide preclinical proof-of-concept for combined FXR and PPAR-α/δ agonist-based therapies in NASH.
|
31227742 |
2019 |
Fatty Liver Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Therefore, this study for the first time explored the preventive effect of trans-chalcone on NASH through the modulation of sterol regulatory element binding protein (SREBP)-1c, SREBP-2, hepatic fatty acid synthesis (FAS) enzyme, proliferator-activated receptor (PPAR)-α, and PPAR-γ2 levels, which are involved in hepatic lipid metabolism.
|
30551380 |
2019 |
Fatty Liver Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Osthole, a coumarin derivative, can increase hepatic peroxisome proliferator-activated receptor α (PPARα) expression and reduce hepatic steatosis and inflammatory response in rats with non-alcoholic steatohepatitis (NASH).
|
30659956 |
2019 |
Fatty Liver Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Saroglitazar, a dual PPARα/γ agonist with predominant PPARα activity, shows an overall improvement in NASH.
|
29164820 |
2018 |
Fatty Liver Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Silibinin can ameliorate some metabolic alterations and induce some molecular changes by activating the CFLAR-JNK pathway and thereby regulating its downstream target genes involved in lipid metabolism (PPARα, SREBP-1C and PNPLA3), glucose uptake (PI3K-AKT), oxidative stress (NRF2, CYP2E1, CYP4A) and inflammatory response(NO) in OA-treated HepG2 cells demonstrating its possible use in ameliorating various symptoms of NASH.
|
30248539 |
2018 |
Fatty Liver Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Alterations in downstream protein expression pointed to significant activation of transforming growth factor β, SMAD family member 3, β-catenin, Nrf2, SREBP-LXRα and nuclear receptor-interacting protein 1 (NRIP1), and inhibition of PPARs and p53 in human NASH biopsies and/or HCCs, suggesting their involvement in accumulation of lipids, development of fibrosis, oxidative stress, cell proliferation and suppression of apoptosis in NASH hepatocarcinogenesis.
|
28218651 |
2017 |
Fatty Liver Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In a complementary fast food (FF) diet NASH model, mimicking features of the metabolic syndrome, miR-21 levels increase in both liver and muscle, concomitantly with decreased expression of peroxisome proliferator-activated receptor α (PPARα), a key miR-21 target.
|
28406477 |
2017 |
Fatty Liver Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The efficacy of peroxisome proliferator-activated receptor α-agonists (e.g., fibrates) against nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) in humans is not known.
|
28195199 |
2017 |
Fatty Liver Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Hepatic miR-141 and miR-200c RNA levels were highly induced in human patients with NASH fatty liver and in WT MCD mice. miR-141/200c-/- MCD mice had reduced liver weights and triglyceride (TG) levels, which was associated with increased microsomal TG transfer protein (MTTP) and PPARα but reduced SREBP1c and FAS expression.
|
29093267 |
2017 |
Fatty Liver Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We established a mouse model of developmental nonalcoholic steatohepatitis (NASH) by feeding a high polyunsaturated fat liquid diet to female glutathione-S-transferase 4-4 (Gsta4<sup>-/-</sup>)/peroxisome proliferator activated receptor α (Ppara<sup>-/-</sup>) double knockout 129/SvJ mice for 12 weeks from weaning.
|
27998724 |
2017 |
Fatty Liver Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Liver PPARα expression negatively correlated with the presence of NASH (p=0.001) and with severity of steatosis (p=0.003), ballooning (p=0.001), NASH activity score (p=0.008) and fibrosis (p=0.003).
|
25703085 |
2015 |
Fatty Liver Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The increased expression of CB1 in NASH and the negative correlation with PPARα suggest a deleterious role of CB1 in NAFLD.
|
24864249 |
2014 |
Fatty Liver Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Amelioration by chicory seed extract of diabetes- and oleic acid-induced non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) via modulation of PPARα and SREBP-1.
|
23603006 |
2013 |
Fatty Liver Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Moreover, PPARα expression was required for the fenofibrate-induced protection against NASH.
|
21474829 |
2011 |
Fatty Liver Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Neither NASH nor genotype 1 HCV-related liver steatosis seems to be associated with the PPARalpha L162V polymorphism.
|
16297361 |
2005 |